TECH logo

Bio-Techne Corporation

TECH
Healthcare|Biotechnology|US
$72.78
+0.12 (+0.17%)
DCF Value
$23.03
Tangible Book / Share
$5.78
Graham Number
$18.46
Cash / Share
$2.23

About

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Stock Price

+25.1%(1Y)
1M
+0.5%
3M
+0.7%
6M
+50.5%
YTD
+23.8%
1Y
+26.7%
3Y
+24.0%
5Y
-42.5%

Pipeline Summary

1 total trials
0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Not Yet Recruiting: 1

Key Facts

Market Cap$11.43B
Employees3,000 (-3% YoY)
CEOKim Kelderman
IPO DateFeb 9, 1989
Beta1.27
52-Week Range$43.2 – $72.83
Avg Volume3,193,854
ExchangeNASDAQ

Ownership

Float99.4%
Shares Outstanding157.1M

Recent Insider Trades

Kelderman KimTAX W/H
Nov 1, 20262,385 shares @ $72.66
Hippel JamesOPTION EX.
Nov 1, 202611,545 shares
Hippel JamesTAX W/H
Nov 1, 20265,096 shares @ $72.66
Hippel JamesOPTION EX.
Nov 1, 202611,545 shares
Hippel JamesOPTION EX.
Aug 15, 20269,980 shares

Peers

AAgilent Technologies, Inc.
$49.28B
ALMRAlamar Biosciences, Inc.
$1.95B
BIOBio-Rad Laboratories, Inc.
$10.25B
BRKRBruker Corporation
$9.34B
DHRDanaher Corporation
$161.86B
QGENQiagen N.V.
$10.39B
RVTYRevvity, Inc.
$17.31B
SEERSeer, Inc.
$90.3M

Recent News

BIO-TECHNE DECLARES DIVIDEND
Nov 3, 2026 · prnewswire.com
Press release: CMB.TECH fleet update
Oct 13, 2026 · globenewswire.com
CMB.TECH SPECIAL GENERAL MEETING RESULTS
Oct 8, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:36 AM